Roche Holding Ag released new treatment data which was presented at the European Cancer Conference in Barcelona.

HER2-positive breast cancer, is rare but highly aggressive, often leading to a total mastectomy.

Results from the NeoAdjuvant study showed that the complete disappearance of the tumor in the breast was achieved for 55% of patients given a combination of Herceptin and chemotherapy. Only 19% of patients that received chemotherapy without Herceptin achieved complete disappearance of the tumor.

The drug is marketed in the United States by Genentech.

Rating 3.00 out of 5
[?]